TNF and inflammatory bowel disease: In Europe and North America, outside of the influence of systemic structural barriers such as complex reimbursement and insurance policies, there are HCP-level actions that can be made now to support better use of biosimilar anti-TNF-α medicines in early IBD treatment and, thus, accelerated treatment initiation and long-term optimized outcomes.